title: Vulvar Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.
abstract: Vulvar cancer is a rare gynecologic malignancy. Ninety percent of vulvar cancers are predominantly squamous cell carcinomas (SCCs), which can arise through human papilloma virus (HPV)-dependent and HPV-independent pathways. The NCCN Vulvar Cancer panel is an interdisciplinary group of representatives from NCCN Member Institutions consisting of specialists in gynecological oncology, medical oncology, radiation oncology, and pathology. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Vulvar Cancer provide an evidence- and consensus-based approach for the management of patients with vulvar SCC. This manuscript discusses the recommendations outlined in the NCCN Guidelines for diagnosis, staging, treatment, and follow-up.
authors.forename: Wui-Jin
authors.initials: WJ
authors.lastname: Koh
authors.forename: Benjamin E
authors.initials: BE
authors.lastname: Greer
authors.forename: Nadeem R
authors.initials: NR
authors.lastname: Abu-Rustum
authors.forename: Susana M
authors.initials: SM
authors.lastname: Campos
authors.forename: Kathleen R
authors.initials: KR
authors.lastname: Cho
authors.forename: Hye Sook
authors.initials: HS
authors.lastname: Chon
authors.forename: Christina
authors.initials: C
authors.lastname: Chu
authors.forename: David
authors.initials: D
authors.lastname: Cohn
authors.forename: Marta Ann
authors.initials: MA
authors.lastname: Crispens
authors.forename: Don S
authors.initials: DS
authors.lastname: Dizon
authors.forename: Oliver
authors.initials: O
authors.lastname: Dorigo
authors.forename: Patricia J
authors.initials: PJ
authors.lastname: Eifel
authors.forename: Christine M
authors.initials: CM
authors.lastname: Fisher
authors.forename: Peter
authors.initials: P
authors.lastname: Frederick
authors.forename: David K
authors.initials: DK
authors.lastname: Gaffney
authors.forename: Ernest
authors.initials: E
authors.lastname: Han
authors.forename: Susan
authors.initials: S
authors.lastname: Higgins
authors.forename: Warner K
authors.initials: WK
authors.lastname: Huh
authors.forename: John R
authors.initials: JR
authors.lastname: Lurain
authors.forename: Andrea
authors.initials: A
authors.lastname: Mariani
authors.forename: David
authors.initials: D
authors.lastname: Mutch
authors.forename: Christa
authors.initials: C
authors.lastname: Nagel
authors.forename: Larissa
authors.initials: L
authors.lastname: Nekhlyudov
authors.forename: Amanda Nickles
authors.initials: AN
authors.lastname: Fader
authors.forename: Steven W
authors.initials: SW
authors.lastname: Remmenga
authors.forename: R Kevin
authors.initials: RK
authors.lastname: Reynolds
authors.forename: Todd
authors.initials: T
authors.lastname: Tillmanns
authors.forename: Stefanie
authors.initials: S
authors.lastname: Ueda
authors.forename: Fidel A
authors.initials: FA
authors.lastname: Valea
authors.forename: Emily
authors.initials: E
authors.lastname: Wyse
authors.forename: Catheryn M
authors.initials: CM
authors.lastname: Yashar
authors.forename: Nicole
authors.initials: N
authors.lastname: McMillian
authors.forename: Jillian
authors.initials: J
authors.lastname: Scavone
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001706:Biopsy; D002294:Carcinoma, Squamous Cell / Q000175:diagnosis* / Q000453:epidemiology / Q000473:pathology / Q000628:therapy*; D059248:Chemoradiotherapy; D005260:Female; D006801:Humans; D008495:Medical Oncology / Q000592:standards; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis* / Q000628:therapy; D009367:Neoplasm Staging; D030361:Papillomavirus Infections / Q000175:diagnosis* / Q000453:epidemiology / Q000473:pathology / Q000628:therapy*; D018714:Radiotherapy, Adjuvant; D012307:Risk Factors; D015996:Survival Rate; D014846:Vulvar Neoplasms / Q000175:diagnosis* / Q000453:epidemiology / Q000473:pathology / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents